Smith CI - Search Results

1

High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.

Islam TC, Asplund AC, Lindvall JM, Nygren L, Liden J, Kimby E, Christensson B, Smith CI, Sander B. Islam TC, et al. Among authors: smith ci. Leukemia. 2003 Sep;17(9):1880-90. doi: 10.1038/sj.leu.2403057. Leukemia. 2003. PMID: 12970790

2

Genetically modified autoactivated cells expressing intracellular forms of GM-CSF as a model for regulated administration of cytokines.

Arteaga HJ, Mohamed AJ, Christensson B, Mahdy E, Gahrton G, Smith CI, Dilber MS. Arteaga HJ, et al. Among authors: smith ci. Scand J Immunol. 2005 Nov;62(5):429-36. doi: 10.1111/j.1365-3083.2005.01687.x. Scand J Immunol. 2005. PMID: 16305639 Free article.

3

Targets for Ibrutinib Beyond B Cell Malignancies.

Berglöf A, Hamasy A, Meinke S, Palma M, Krstic A, Månsson R, Kimby E, Österborg A, Smith CI. Berglöf A, et al. Among authors: smith ci. Scand J Immunol. 2015 Sep;82(3):208-17. doi: 10.1111/sji.12333. Scand J Immunol. 2015. PMID: 26111359 Free PMC article. Review.

4

Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.

Hamasy A, Wang Q, Blomberg KE, Mohammad DK, Yu L, Vihinen M, Berglöf A, Smith CI. Hamasy A, et al. Among authors: smith ci. Leukemia. 2017 Jan;31(1):177-185. doi: 10.1038/leu.2016.153. Epub 2016 May 25. Leukemia. 2017. PMID: 27282255 Free PMC article.

5

Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.

Vargas L, Hamasy A, Nore BF, Smith CI. Vargas L, et al. Among authors: smith ci. Scand J Immunol. 2013 Aug;78(2):130-9. doi: 10.1111/sji.12069. Scand J Immunol. 2013. PMID: 23672610 Free article. Review.

6

From identification of the BTK kinase to effective management of leukemia.

Smith CI. Smith CI. Oncogene. 2017 Apr;36(15):2045-2053. doi: 10.1038/onc.2016.343. Epub 2016 Sep 26. Oncogene. 2017. PMID: 27669440 Free PMC article. Review.

7

Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma.

Alici E, Björkstrand B, Treschow A, Aints A, Smith CI, Gahrton G, Dilber MS. Alici E, et al. Among authors: smith ci. Cancer Gene Ther. 2007 Mar;14(3):227-32. doi: 10.1038/sj.cgt.7701006. Epub 2006 Nov 3. Cancer Gene Ther. 2007. PMID: 17082794

8

Bioplex technology: novel synthetic gene delivery pharmaceutical based on peptides anchored to nucleic acids.

Simonson OE, Svahn MG, Törnquist E, Lundin KE, Smith CI. Simonson OE, et al. Among authors: smith ci. Curr Pharm Des. 2005;11(28):3671-80. doi: 10.2174/138161205774580813. Curr Pharm Des. 2005. PMID: 16305503 Review.

9

Express subcutaneous IgG infusions: decreased time of delivery with maintained safety.

Hansen S, Gustafson R, Smith CI, Gardulf A. Hansen S, et al. Among authors: smith ci. Clin Immunol. 2002 Sep;104(3):237-41. doi: 10.1006/clim.2002.5215. Clin Immunol. 2002. PMID: 12217333

10

Adding functional entities to plasmids.

Svahn MG, Lundin KE, Ge R, Törnquist E, Simonson EO, Oscarsson S, Leijon M, Brandén LJ, Smith CI. Svahn MG, et al. Among authors: smith ci. J Gene Med. 2004 Feb;6 Suppl 1:S36-44. doi: 10.1002/jgm.510. J Gene Med. 2004. PMID: 14978749 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

629 results

Search Page

Filters